Opioid receptor (OR) antagonist naltrexone is a medicine that has been approved by the FDA for the treatment of opioid and alcohol use disorders when taken in the usual doses. Naltrexone, on the other hand, has been found to have unique applications in inflammatory, neoplastic, insulin sensitivity-related, and chronic pain diseases since the identification of the effects of OR signalling at low doses that are not neuropsychiatric in nature. Its harmful effects are also mitigated when it's taken in smaller dosages. Its use outside of the manufacturer's instructions in the aforementioned scenarios has been shown to be cost-effective in comparison to expensive immunomodulation and anticancer medications. Because of its cheaper cost and extremely low margin of interest, in-depth research on the topic has been prevented by the pharmaceutical industry. Animal studies, cell culture studies, and case reports are the only types of research that have been carried out so far; some of these types of research have shown encouraging results. There are not nearly enough high-quality trials being conducted.